6533b85cfe1ef96bd12bc7dd

RESEARCH PRODUCT

Nonsurgical treatments for primary liver carcinoma in elderly patients: a 12-year retrospective study

subject

description

Introduction: Cancer is a leading cause of death. 70 percent of cases develop over the age of 65. Although a few patients with metastatic cancer are potentially resectable for cure (particularly those with isolated metastases), treatment for most patients is palliative and generally consists of systemic chemotherapy asoociated to target therapy. Objectives: To evaluate efficacy, safety and outcome of the addition of bevacizumab to chemotherapy in advanced cancer in elderly patients, a prospective study was carried on the last four years at Gonesse Hospital Group. Methods: Patients older than 65year with advanced metastatic (Stage IV) cancer (fourteen colorectal carcinoma, five breast carcinoma and one ovarian carcinoma) were assigned to be treated with bevacizumab associated to chemotherapy for at least six month. Primary end point was the overall survival at 2 years. Tolerability was defined by toxicity measurement in the end of study. Results: Between 2008 and 2013, twenty patients (seven men and thirteen women) were enrolled. The median age was 77 years (ranged between 65 to 80). The geriatric standardized evaluation was favourable to treatment with chemotherapy associated with bevacizumab. The overall survival at 2 year was 54 %. One year’s follow-up after completion of study treatment, all patients continued to be alive with disease progression. Fifteen patients remained alive with distant progressive disease. Among all patients, 17 patients had a hematologic toxicity grade I and 17 patients had an arterial hypertension. Conclusion: The addition of bevacizumab to chemotherapy was a beneficial option in treatment of advanced cancer in elderly patients.